He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Subscribe To Our Newsletter & Stay Updated
